Volume 73, Issue 4, Pages e116-e118 (April 2018)

Slides:

Advertisements

Similar presentations

CheckMate 025: A randomized, open-label, phase III study of nivolumab versus everolimus in advanced renal cell carcinoma Padmanee Sharma, Bernard Escudier,

Advertisements

Volume 60, Issue 4, Pages (October 2011)

Volume 60, Issue 5, Pages (November 2011)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis Maria I. Carlo, Darren R.

European Urology Focus

Testosterone Therapy in Men With Prostate Cancer

Volume 70, Issue 6, Pages (December 2016)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Volume 53, Issue 4, Pages (April 2008)

Volume 70, Issue 6, Pages (December 2016)

The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks Marcus G.

Volume 73, Issue 3, Pages (March 2018)

Volume 51, Issue 4, Pages (April 2007)

Volume 69, Issue 1, Pages (January 2016)

Volume 69, Issue 1, Pages 4-6 (January 2016)

Volume 54, Issue 4, Pages (October 2008)

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Volume 68, Issue 1, Pages (July 2015)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Giuseppe Di Lorenzo, Riccardo Autorino, Cora N. Sternberg

Volume 63, Issue 1, Pages (January 2013)

Volume 63, Issue 4, Pages e53-e56 (April 2013)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 66, Issue 2, Pages (August 2014)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 51, Issue 3, Pages (March 2007)

Volume 71, Issue 3, Pages (March 2017)

Volume 61, Issue 4, Pages (April 2012)

Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma

Volume 68, Issue 1, Pages (July 2015)

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma Viktor Grünwald, Xun Lin, Daniel Kalanovic,

Volume 69, Issue 4, Pages (April 2016)

Volume 60, Issue 5, Pages (November 2011)

Volume 57, Issue 4, Pages e41-e42 (April 2010)

International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia Brett Delahunt, John R. Srigley, Lars Egevad,

Volume 65, Issue 6, Pages (June 2014)

Yuanshan Cui, Yong Zhang European Urology

Volume 61, Issue 6, Pages (June 2012)

Volume 74, Issue 3, Pages (September 2018)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Validation of Preoperative Nomograms Predicting Lymph Node Involvement in Prostate Cancer: A Bi-institutional Study Alexander I. Hinev, Vesselin I. Hadjiev,

Volume 70, Issue 2, Pages (August 2016)

Volume 66, Issue 6, Pages (December 2014)

Leonard S. Marks, Jiaoti Huang European Urology

Volume 53, Issue 4, Pages (April 2008)

Volume 71, Issue 1, Pages (January 2017)

Volume 68, Issue 6, Pages e134-e135 (December 2015)

Volume 68, Issue 4, Pages (October 2015)

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 62, Issue 3, Pages (September 2012)

Volume 50, Issue 5, Pages (November 2006)

Volume 73, Issue 4, Pages e116-e118 (April 2018)

Volume 70, Issue 6, Pages (December 2016)

Volume 54, Issue 4, Pages (October 2008)

Bernard Escudier European Urology Supplements

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 59, Issue 4, Pages (April 2011)

Volume 68, Issue 5, Pages (November 2015)

The Start-Up of the Platinum Journal: A Fascinating Challenge

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

Joaquim Bellmunt European Urology Supplements

European Urology Oncology

Volume 76, Issue 1, Pages (July 2019)

Volume 54, Issue 1, Pages (July 2008)

European Urology Oncology

Volume 51, Issue 5, Pages (May 2007)

Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma Guillermo de Velasco, Axel Bex, Laurence Albiges, Thomas Powles, Brian.

Presentation transcript:

Volume 73, Issue 4, Pages e116-e118 (April 2018) Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] Bernard Escudier, Padmanee Sharma, David F. McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Howard Gurney, Frede Donskov, Katriina Peltola, John Wagstaff, Thomas C. Gauler, Takeshi Ueda, Huanyu Zhao, Ian M. Waxman, Robert J. Motzer European Urology Volume 73, Issue 4, Pages e116-e118 (April 2018) DOI: 10.1016/j.eururo.2017.12.016 Copyright © 2017 Terms and Conditions

Fig. 1A correct version published in the updated online article in December 2017–Forest plot of overall survival by baseline characteristics (risk group, age group, number and sites of metastases, prior therapy). CI=confidence interval; IL-2=interleukin-2; IMDC=International Metastatic Renal Cell Carcinoma Database Consortium; MSKCC=Memorial Sloan Kettering Cancer Center; ORR=overall response rate; OS=overall survival. European Urology 2018 73, e116-e118DOI: (10.1016/j.eururo.2017.12.016) Copyright © 2017 Terms and Conditions

Fig. 1A incorrect version as printed and originally published online–Forest plot of overall survival by baseline characteristics (risk group, age group, number and sites of metastases, prior therapy). CI=confidence interval; IL-2=interleukin-2; IMDC=International Metastatic Renal Cell Carcinoma Database Consortium; MSKCC=Memorial Sloan Kettering Cancer Center; ORR=overall response rate; OS=overall survival. European Urology 2018 73, e116-e118DOI: (10.1016/j.eururo.2017.12.016) Copyright © 2017 Terms and Conditions